Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2

Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead to functional homologous recombination repair (HRR) and olaparib...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Rytelewski, Mateusz, Vareki, Saman Maleki, Mangala, Lingegowda S., Romanow, Larissa, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Christian, Lopez-Berestein, Gabriel, Figueredo, Rene, Ferguson, Peter J., Vincent, Mark, Sood, Anil K., Koropatnick, James D.
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4991495/
https://ncbi.nlm.nih.gov/pubmed/26959114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7883
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker